Men's Health
Conference Coverage
New guideline gives active surveillance a boost
This is the first guidance for localized prostate cancer since 2017.
Conference Coverage
Most men with low-risk prostate tumors now forgoing treatment
Roughly 60% of men eligible for active surveillance chose that approach in 2021, up from 27% in 2014 and less than 10% in 2010.
Conference Coverage
Abaloparatide works in ‘ignored population’: Men with osteoporosis
Study finds increased bone mineral density from baseline to 1 year in men with osteoporosis.
Latest News
Colorado law would lift veil of secrecy on sperm donations
Advocates point out that in addition to the benefits of knowing one’s genetic identity, the anonymity of sperm donors has been scuttled by the...
From the Journals
Is it time to remove ‘cancer’ label from low-risk prostate tumors?
Experts argue that overtreatment could be reduced by removing the word “cancer” from low-risk disease.
Latest News
You want me to tan my WHAT, Tucker Carlson?
“Tanning your scrotal sack and calling it ‘testicle tanning,’ is like tanning your abdominal skin and calling it ‘liver tanning.’”
Latest News
Real-world data suggest coprescribing PDE5 inhibitors and nitrates may be safe
There is a scarcity of real-world data showing that using the two types of drugs together increase cardiovascular risks, according to researchers...
From the Journals
Erectile dysfunction drugs linked to ocular conditions
“Generally speaking, if [patients taking these agents] experience visual problems or changes in vision, then these drugs may be the culprits, and...
Feature
Sex differences in COPD slow to be recognized, treated
News from the FDA/CDC
FDA OKs first condom for anal sex
Though the CDC has long encouraged the use of a condom during anal intercourse, the FDA had not until now deemed this practice safe.
Commentary
Exploring the relationship of COVID-19 vaccines and fertility
The general public has conflated a side effect of the virus, namely, infertility and erectile dysfunction, with that of the vaccine.